Trial Condition(s):
Postmenopause, Pharmacokinetics
Study to assess drospirenone's (DRSP) potential to inhibit Cytochrome P450 3A4 in healthy postmenopausal women
Bayer Identifier:
91222
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
25
Trial Dates
Phase
1
Could I receive a placebo?
No
Products
Drospirenone (DRSP, BAY86-5131)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
Double-blind, randomized, crossover study to assess drospirenone's (DRSP) potential to inhibit Cytochrome P450 3A4 by evaluating the interaction between DRSP at steady state and single doses of the model substrate midazolam in healthy postmenopausal women
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
